Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
Stephen D. Wiviott, Eugene Braunwald, Carolyn H. McCabe, Gilles Montalescot, Witold Rużyłło, Shmuel Gottlieb, F.-J. Neumann, Diego Ardissino, Stefano De Servi, Sabina A. Murphy, Jeffrey Riesmeyer, Govinda J. Weerakkody, Charles Michael Gibson, Elliott Marshall Antman
New England Journal of Medicine · 2007 · 6,831 citationsOpen access
No retraction on record in OpenAlex.Check Crossref now
Cite this paper
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Rużyłło, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., Servi, S. D., Murphy, S. A., Riesmeyer, J., Weerakkody, G. J., Gibson, C. M., & Antman, E. M. (2007). Prasugrel versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine, 357(20), 2001–2015. https://doi.org/10.1056/nejmoa0706482
In text: (Wiviott et al., 2007)
Ask a question about this research
One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.
Abstract
BACKGROUND: Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention. METHODS: To compare prasugrel, a new thienopyridine, with clopidogrel, we randomly assigned 13,608 patients with moderate-to-high-risk acute coronary syndromes with scheduled percutaneous coronary intervention to receive prasugrel (a 60-mg loading dose and a 10-mg daily maintenance dose) or clopidogrel (a 300-mg loading dose and a 75-mg daily maintenance dose), for 6 to 15 months. The primary efficacy end point was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The key safety end point was major bleeding. RESULTS: The primary efficacy end point occurred in 12.1% of patients receiving clopidogrel and 9.9% of patients receiving prasugrel (hazard ratio for prasugrel vs. clopidogrel, 0.81; 95% confidence interval [CI], 0.73 to 0.90; P<0.001). We also found significant reductions in the prasugrel group in the rates of myocardial infarction (9.7% for clopidogrel vs. 7.4% for prasugrel; P<0.001), urgent target-vessel revascularization (3.7% vs. 2.5%; P<0.001), and stent thrombosis (2.4% vs. 1.1%; P<0.001). Major bleeding was observed in 2.4% of patients receiving prasugrel and in 1.8% of patients receiving clopidogrel (hazard ratio, 1.32; 95% CI, 1.03 to 1.68; P=0.03). Also greater in the prasugrel group was the rate of life-threatening bleeding (1.4% vs. 0.9%; P=0.01), including nonfatal bleeding (1.1% vs. 0.9%; hazard ratio, 1.25; P=0.23) and fatal bleeding (0.4% vs. 0.1%; P=0.002). CONCLUSIONS: In patients with acute coronary syndromes with scheduled percutaneous coronary intervention, prasugrel therapy was associated with significantly reduced rates of ischemic events, including stent thrombosis, but with an increased risk of major bleeding, including fatal bleeding. Overall mortality did not differ significantly between treatment groups. (ClinicalTrials.gov number, NCT00097591 [ClinicalTrials.gov].)
Related papers
- Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study2004
- Tissue Plasminogen Activator for Acute Ischemic Stroke1995
- 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation2017
- Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association2019
- Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium.1986
Metadata from OpenAlex (CC0). Citations are generated from the published record.